ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Grothey on Trastuzumab for Gastroesophageal Cancer

Axel Grothey, MD
Published: Monday, Nov 07, 2011

Axel Grothey, MD, Professor of Oncology, Consultant, Medical Oncology, Mayo Clinic, discusses the first-line use of the targeted agent trastuzumab (Herceptin) to treat HER2-positive gastroesophageal cancer.

Trastuzumab is the first targeted agent to be used as a first-line therapy in gastroesophageal cancer. All patients with the disease should now be test for an overexpression of HER2. If patients are HER2-positive trastuzumab should be added to the standard chemotherapy, which is usually 5-fluorouracil and platinum agents such as cisplatin.

Axel Grothey, MD, Professor of Oncology, Consultant, Medical Oncology, Mayo Clinic, discusses the first-line use of the targeted agent trastuzumab (Herceptin) to treat HER2-positive gastroesophageal cancer.

Trastuzumab is the first targeted agent to be used as a first-line therapy in gastroesophageal cancer. All patients with the disease should now be test for an overexpression of HER2. If patients are HER2-positive trastuzumab should be added to the standard chemotherapy, which is usually 5-fluorouracil and platinum agents such as cisplatin.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x